 Nigerian Bioscientist (http://nigerianbioscientist.com)

Histomorphometric effects of chloroquine on the brain (cerebral cortex) of Sprague – Dawley

Akinribido F.A, Noronha C.C, Okanlawon O.A (2011)
Dept Department of Biological Sciences, Bells University of Technology Ota, Ogun State
Dept Of Anatomy,College of Medicine, University of Lagos, Idi-Araba, Lagos State
(Research Work)
Correspondence to: Akinribido F.A, fumibos@yahoo.co.uk; +2348023654975

ABSTRACT

Chloroquine had been reported to cause retinopathy, cochlea vestibular dysfunction these are being controlled by the brain. It is therefore necessary to study its effects on the brain (Taylor and Francis 1987).Hence this study was designed to determine the histomorphometric effects of administration of chloroquine on the brain. Ten male rats were exposed to chloroquine (intraperitoneally/IP) for three days. The treated rats received 0.125/100g body weight of chloroquine phosphate injection intraperitoneally. Control rats received the same amount of normal saline intraperitoneally.

The histology of the chloroquine treated rats brain was compared with controls, there were few pyramidal cells and martinotti cells in the treated rats compared with controls. It was observed that chloroquine caused shrinkages and contrition in the pyramidal cells of the brain (cerebral cortex) and cells of martinotti of the cerebral cortex.

Stereologically, the estimated absolute volume $\mathbf{V=V_{V(structure)} \times V_{(ref)}}$
of pyramidal cells was determined and compared. Chloroquine caused a reduction in the absolute volume of treated brain pyramidal cells compared with controls.

Keywords: Chloroquine, Sprague-Dawley rats, brain (cerebral cortex), histology, stereology.

INTRODUCTION

Approximately 50-70% of chloroquine in plasma is bound to plasma proteins. The tissues exhibit particularly high binding to chloroquine especially those containing melanin, for example the retina. Significant binding also occurs in the liver, kidney and spleen. Chloroquine (Resochin,Avloclor, Nivaquine, Arelen) $C_{18}H_{26}CIN_3$ 7- Chloro -4- (4'- diethlyamino-1'-methylamino0 quinoline. Chloroquine is a white powder with a bitter taste, prepared by chemical synthesis .it is available as sulphate and phosphate salts. The sulphate (1 in 3) and the phosphate (1 in 4) are soluble in water. Chloroquine is best known as an antimalarial agent but it is also used in the treatment of rheumatoid arthritis. Chloroquine is effective against the erythrocytic stages of all four plasmodium species which cause human malaria with the exception of matured plasmodium falciparum gametocytes. The exact mechanisms of the action of chloroquine against malaria parasites are not fully understood. Parasitized red cells accumulate approximately 100-600 times as much chloroquine. The concentration of chloroquine in malaria parasite requires energy and is thought to require a membrane. There are three theories on the way state as that chloroquine, being a basic compound, is protonated in the lysosomes thus raising lysosomal pH. This effect may raise the intralysosomal pH above a critical level all bring about loss lysosomal function. This would reduce the parasite's digestion of heamoglobin, and thus prevent its growth.

Chloroquine intercalates into double stranded DNA and inhibits both DNA and RNA synthesis. The intercalation theory suggests that chloroquine may be bound with increased affinity by certain parts of the genome and be toxic to the malaria parasite by selective accumulation in specific genes, inhibiting their expression. The ferriprotorphyrin IX (FP) which inhibits sequestration of FP into malaria pigment. This could impair heamoglobin degradation and permits damage to the food vacuole sufficient to discharge its Ph

gradient.antimalaria activity is possessed equally by the enantiomers of chloroquine and the main metabolite desethlychloroquine is also active against chloroquine- sensitive Plasmodiam. Chloroquine also has anti-inflammatory activity. The concentrations of chloroquine or hydrochloroquine found in serum in the treatment of rheumatoid disease raise the pH of acid vesicles in mammalian cell within 3-5 min in vitro. This and the observation that the view that chloroquine and hydoxychloroquine act in the rheumatic disease by raising the pH of acid vesicles. Effects of raised vesicle pH include inhibition lysosomal proteolysis, interference with the targeting of acid proteases and inhibition of cellular maturation .raise pH in the macrophage vesicle can interfere with antigen processing. This is thought to be the explanation for the impaired antibody response to pre-exposure to human diploid cell rabies vaccine found in individual receiving concurrent chemoprophyaxis with chloroquine. In addition, chloroquine inhibits the chemotactic response of mononuclear cells and suppresses lymphocytes transformation.

MATERIALS AND METHODS

The twenty male Sprague- Dawley rats were collected from the Animal House of the College of Medicine University of Lagos Akoka, Lagos State.

They weighed between 100-150g and were fed with the normal rat feed from Pfizer PLC Ikeja Lagos. Weight of animals was taken twice daily throughout the duration of the experiment. Ten female rats were used as controls. The remaining ten female rats were labelled by ear puncture as treated rats and kept in cages. Administration of drug was 0.125ml of chloroquine /100g body weight for 3 days intrapertoneally. Chloroquine phosphate injection was obtained from the community pharmacy of the Lagos University Teaching Hospital (40mg/ml chloroquine phosphate injection).The control received the same quantity of normal saline.

Animal Sacrifice

At the expiration of the treatment the animals were sacrificed by diethyl ether decapitation and the brain was removed for morphological and histological assessment.

Histological Analysis

The twenty male rats were sacrificed as discussed earlier after treatment with the chloroquine phosphate injection .The brain was removed and fixed in Bouin's fluid. The specimen of equal length was cut transversely and longitudinally into serial cross sections of 3µm normal thickness with Reichert Jung Supercut Mictrotome for control and treated rats. The tissue was sectioned using tissues preparation tissues method with heamatoxylin and eosin stains and examined the light binocular microscope at a magnification of 100 and 400 respectively.

Stereological Analysis

The vertical sections of the histochemical preparation of stratum length of 0.5cm from 10 control and 10 treated rats brain was made at a final print magnification of 100 and 400 respectively.

5 slides will be obtained from the control and 5 slides from the treated rats.

For each of the fractions, the N_T/A □ number of test points counted on rat's brain pyramidal cells, per unit area of the fractions were estimated by point counting method using the forbidden rule Hans Gundersen,1977) which states that any structure that touches the forbidden line must not be counted. The reference volume V(ref) of brain pyramidal cells was estimated by point counting (Wiebel, 1979, Gundersen et al, 1988).

At Magnification (M) = 100 final magnification using a <u>Square Grid</u> of test point diameter (d) =1.2cm apart. The test system used in the light microscopic analysis within a square frame measuring 20cm x 20cm onto which microscopic image was projected using a wild leitz microscope equipped with a mirror at a magnification of 25 on a white screen.

Downloaded from Nigerianbioscientist.com- Online resources for bioscientists!

Estimated V(ref) = (stratum length) x $\frac{d^2}{M^2}$ x mean N_T/A (structure).

d= diameter of test grid

M=magnification of projection

The relevant volume density of brain pyramidal cells of the fractions Vv (structure) were estimated on the same section at a final magnification of 100. Each field was projected onto a test system consisting of three sets of points with numerical densities in the ratio 1:4:16. The corresponding distance between the test points of each set were 4.8, 2.4 and 1.2cm respectively.

The criteria for test point design and allocation were based on efficiency considerations; thus approximately the same number of test points (which does not need to exceed 200) should be in each structure within each organ (Gundersen and Jensen, 1987; Gundersen et al ., 1988; Cruz Orive and Wiebel; 1990). The required volume density of the fractions were estimated as follows:

Estimated Vv(structure) = Nv_R x N_T/A(structure)

Vv = volume density Nv_R = numerical density ratio

Finally, the absolute volume of brain pyramidal cells was estimated using this equation.

V(structure) =Vv (structure) x V (ref)

V(structure) = Absolute volumes of structure
Vv(ref) = Reference volume of structure

STATISTICS
Statistical analysis was carried out using t- Distribution (t- test).

RESULTS
Table1: Mean Number Ot Test Points Per Unit Area (N_t/A) Of Brain Pyramidal Cells

GROUP n=20	Mean (N_T/A)
CONTROL (CO)	13.5
CHLOROQUINE TREATED (CQ)	5.5

CO=CONTROL RATS
CQ= CHLOROQUINE TREATED RATS

Table2: Mean Estimated Absolute Volumes (Cm^3) Of Brain Pyramidal Cells

TISSUE	CONTROL RATS n=10	CHLOROQUINE TREATED RATS n=10
BRAIN (PYRAMIDAL CELLS)	$3.28 \times 10^{-3} \pm 5.52^{a}$	$5.45 \times 10^{-4} \pm 2.31^{b}$

Downloaded from Nigerianbioscientist.com- Online resources for bioscientists!

a=Mean±S.E.M

b=$p<0.05$

DISCUSSION

Histomorphometric effects

Chloroquine caused a defect in the microscopic structures of the brain (cerebral cortex) pyramidal cell and cells of martinolti by causing shrinkage and constrictions in these structures. They were few pyramidal and martinolti cells in the treated compared with controls.

Stereologically, the estimated absolute volume of fractions were determined and compared. There was a reduction in the absolute volume of treated brain pyramidal cells compared with controls.

CONCLUSION

This study has demonstrated that chloroquine though an antimalarial drug when taken for a short period have deleterious effects on a vital organ of the body the brain cortex and therefore should only be taken under the supervision of a medical practitioner.

REFERENCES

1. Ajayi A.A (September 2000). "Mechanisms of chloroquine-induced pruritus". *Clin. Pharmacol. Ther.* **68** (3): 336.
2. Cann HM, Verhulst HL (1 January 1961). "Fatal acute chloroquine poisoning in children" (abstract). *Pediatrics* **27** (1): 95–102.
3. CDC. Health information for international travel 2001-2002. Atlanta, Georgia: U.S. Department of Health and Human Services, Public Health Service, 2001.
4. Chen, Patrick; Gombart, Z and Chen J (2011). "Chloroquine treatment of ARPE-19 cells leads to lysosome dilation and intracellular lipid accumulation: possible implications of lysosomal dysfunction in macular degeneration". *Cell & Bioscience* **1** (10).
5. Davidson RJ, Davis I, Willey BM (2008). Frenck, Robert. ed. "Antimalarial therapy selection for quinolone resistance among Escherichia coli in the absence of quinolone exposure, in tropical South America". *PLoS ONE* **3** (7): e2727. Molina DK (2011) Postmortem hydroxychloroquine concentrations in nontoxic cases. Am J Forensic Med Pathol
6. Delhaes L, Benoit-Vical F, Camus D, Capron M, Meunier B. Essentials of medical pharmacology fifth edition 2003,reprint 2004, published by-Jaypee Brothers Medical Publisher Ltd, 2003,KD tripathi, page 739,740.
7. Hempelmann E. (2007). "Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors". *Parasitol Research* **100** (4): 671–676..
8. Kim, Ella; Wustenberg R, Rusbam A, et al (2010). "Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells". *Neuro-oncology* **12** (4).
9. Kurup, Pradeep; Zhang Y, Xu J, et al. (2010). "β-Mediated NMDA Receptor Endocytosis in Alzheimer's Disease Involves Ubiquitination of the Tyrosine Phosphatase STEP61". *Neurobiology of Disease* **30** (17).
10. Lim P, Alker AP, Khim N et al. (2009). "Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia". *Malar. J.* **8**: 11.
11. Martin RE, Marchetti RV, Cowan AI et al.(September 2009). "Chloroquine transport via the malaria parasite's chloroquine resistance transporter". *Science* **325**(5948): 1680-2:
12. Plowe CV (2005). "Antimalarial drug resistance in Africa: strategies for monitoring and deterrence". *Curr. Top. Microbiol. Immunol.* **295**: 55–79.

Downloaded from Nigerianbioscientist.com- Online resources for bioscientists!

13. Premji Z, Umeh RE, Owusu-Agyei S, *et al.* (2009). "Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria". *PLoS ONE* **4** (8): e6682.
14. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R (November 2003). "Effects of chloroquine on viral infections: an old drug against today's diseases?". *Lancet Infect Dis* **3** (11): 722–7.
15. Savarino A, Lucia MB, Giordano F, Cauda R (October 2006). "Risks and benefits of chloroquine use in anticancer strategies". *Lancet Oncol.* **7** (10): 792–3.
16. Sotelo J, Briceño E, López-González MA (March 2006). "Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial". *Ann. Intern. Med.* **144** (5): 337–43.
17. Tshefu AK, Gaye O, Kayentao K, *et al.* (2010). "Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated *Plasmodium falciparum* malaria: a randomised non-inferiority trial". *Lancet* **375** (9724): 1457–1467..
18. Uhlemann AC, Krishna S (2005). "Antimalarial multi-drug resistance in Asia: mechanisms and assessment". *Curr. Top. Microbiol. Immunol.* **295**: 39–53
19. Vugt M, Brockman A, Gemperli B, Luxemburger C, Gathmann I, Royce C, Slight T, Looareesuwan S, White N J, Nosten F. A randomised comparison of artemether-benflumetol and artesunate-mefloquine in the treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother. 1998;42:135–139.
20. White NJ (April 2004). "Antimalarial drug resistance". *J. Clin. Invest.* **113** (8): 1084–92.
21. Yam JC, Kwok AK (August 2006). "Ocular toxicity of hydroxychloroquine". *Hong Kong Med J* **12** (4): 294–304

Downloaded from Nigerianbioscientist.com- Online resources for bioscientists!